President Donald Trump signed an executive order on April 18, 2026, in Washington, D.C., directing the U.S. Food and Drug Administration to accelerate the review of psychedelic drug treatments such as ibogaine and psilocybin [1].

The order matters because it seeks to expand treatment options for mental‑health conditions that have long challenged the U.S. health system, including high rates of depression and post‑traumatic stress disorder among veterans. Faster access could reduce the burden on families and the veteran health network.

The directive instructs the FDA to prioritize clinical trials, streamline the approval pathway, and consider broader prescribing authority for qualified clinicians. It specifically names ibogaine, a plant‑derived compound studied for addiction, and psilocybin, a serotonin‑modulating agent, as priority substances—both of which have shown promise in early‑stage research.

Trump said the move reflects a “new era of medical innovation” aimed at saving lives and restoring hope for those who have served the nation. By targeting veterans, the order aligns with recent congressional efforts to address the mental‑health crisis in the veteran community.

Implementation will depend on the FDA’s capacity to evaluate safety data, coordinate with research institutions, and establish guidelines for controlled use. Critics said the expedited pathways could overlook long‑term risks, and supporters said existing delays have left many patients without effective options.

**What this means**: The order could reshape U.S. drug policy by placing psychedelics on a faster regulatory track, potentially leading to earlier clinical use for depression, PTSD and addiction. If the FDA follows through, the change may spur additional research funding and influence other nations to reconsider their own approval processes. However, the ultimate impact will hinge on rigorous scientific review and how quickly the health system can integrate these treatments safely.

“Fast‑tracking psychedelic drugs could reshape mental‑health treatment.”

The order could reshape U.S. drug policy by placing psychedelics on a faster regulatory track, potentially leading to earlier clinical use for depression, PTSD and addiction. If the FDA follows through, the change may spur additional research funding and influence other nations to reconsider their own approval processes. However, the ultimate impact will hinge on rigorous scientific review and how quickly the health system can integrate these treatments safely.